HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. [electronic resource]
Producer: 20020221Description: 1081-9 p. digitalISSN:- 0923-7534
- Adult
- Aged
- Antigens, Neoplasm
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biomarkers, Tumor -- analysis
- Breast Neoplasms -- chemistry
- Chemotherapy, Adjuvant
- Confidence Intervals
- Cyclophosphamide -- administration & dosage
- DNA Topoisomerases, Type II -- analysis
- DNA-Binding Proteins
- Epirubicin -- administration & dosage
- Female
- Fluorouracil -- administration & dosage
- Genes, erbB-2 -- genetics
- Humans
- Methotrexate -- administration & dosage
- Middle Aged
- Predictive Value of Tests
- Prognosis
- Receptor, ErbB-2 -- analysis
- Retrospective Studies
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.